Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.
about
BRI2 (ITM2b) inhibits Abeta deposition in vivoStructural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrilsAβ42-oligomer Interacting Peptide (AIP) neutralizes toxic amyloid-β42 species and protects synaptic structure and function.Molecular Mechanism of Thioflavin-T Binding to the Surface of β-Rich Peptide Self-AssembliesStructure-based design of non-natural amino-acid inhibitors of amyloid fibril formationMolecular mechanism of Thioflavin-T binding to amyloid fibrilsStructure and dynamics of parallel beta-sheets, hydrophobic core, and loops in Alzheimer's A beta fibrilsComputational design of new Peptide inhibitors for amyloid Beta (aβ) aggregation in Alzheimer's disease: application of a novel methodologyModels of membrane-bound Alzheimer's Abeta peptide assembliesInterprotofilament interactions between Alzheimer's Abeta1-42 peptides in amyloid fibrils revealed by cryoEMA new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modelingModeling the Alzheimer Abeta17-42 fibril architecture: tight intermolecular sheet-sheet association and intramolecular hydrated cavitiesInhibition of Abeta42 aggregation using peptides selected from combinatorial libraries.Molecular structures of quiescently grown and brain-derived polymorphic fibrils of the Alzheimer amyloid abeta9-40 peptide: a comparison to agitated fibrils.Beta-amyloid precursor protein mutants respond to gamma-secretase modulatorsPolymorphic structures of Alzheimer's β-amyloid globulomers.What is the role of amyloid precursor protein dimerization?Mapping the specific cytoprotective interaction of humanin with the pro-apoptotic protein bid.Peptides for therapy and diagnosis of Alzheimer's disease.Polymorphic C-terminal beta-sheet interactions determine the formation of fibril or amyloid beta-derived diffusible ligand-like globulomer for the Alzheimer Abeta42 dodecamer.Amyloid β-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process.Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-β precursor protein dimerizationComparative analysis of the Shadoo gene between cattle and buffalo reveals significant differences.Critique of the use of fluorescence-based reporters in Escherichia coli as a screening tool for the identification of peptide inhibitors of Aβ42 aggregation.Hydralazine modifies Aβ fibril formation and prevents modification by lipids in vitro.The unique Alzheimer's β-amyloid triangular fibril has a cavity along the fibril axis under physiological conditions.Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species.Conformational stability of fibrillar amyloid-beta oligomers via protofilament pair formation - a systematic computational studyAlzheimer's protective A2T mutation changes the conformational landscape of the Aβ₁₋₄₂ monomer differently than does the A2V mutation.Polymorphic triple beta-sheet structures contribute to amide hydrogen/deuterium (H/D) exchange protection in the Alzheimer amyloid beta42 peptideInteraction of amyloid inhibitor proteins with amyloid beta peptides: insight from molecular dynamics simulationsAmyloid polymorphism: structural basis and neurobiological relevance.Structural differences of amyloid-β fibrils revealed by antibodies from phage displaySelf-Assembly of Aβ40, Aβ42 and Aβ43 Peptides in Aqueous Mixtures of Fluorinated Alcohols.Effects of peptides derived from terminal modifications of the aβ central hydrophobic core on aβ fibrillization.Cross-linking of cell surface amyloid precursor protein leads to increased β-amyloid peptide production in hippocampal neurons: implications for Alzheimer's disease.Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15-28 fragment of the Alzheimer amyloid-beta protein.Physiological temperature has a crucial role in amyloid β in the absence and presence of hydrophobic and hydrophilic nanoparticles.Novel therapeutic strategies for the treatment of protein-misfolding diseases.Glycines from the APP GXXXG/GXXXA Transmembrane Motifs Promote Formation of Pathogenic Aβ Oligomers in Cells
P2860
Q24319041-9E7DF1E4-3B4D-4A11-BBA5-FC652C75F4B2Q24631702-C40BEBB0-1A06-467B-9076-B8FB57174B61Q27308119-BCEC1928-827D-49A1-A233-BFDF9F26B548Q27653006-D7D465B4-3BD3-405D-9EC5-172B68FEC826Q27670453-D5141E31-C25A-4055-A516-2B33CB77C8B1Q28279924-3402DB62-9E98-4901-8362-4B631385B321Q28395520-26F59500-6CD0-4EE6-B8FA-7C35A93C2434Q28533731-78F520C3-931D-47A1-831F-D57739EA03D9Q30155996-AF0E98AE-D061-4553-8235-34903FD54D07Q30438461-CB8FB47F-3F5F-4A67-BA29-556DB74BDFC3Q31041418-8551A899-B95F-4549-A083-3A32684215B7Q31120675-0C389AB8-2DC9-4D9B-8510-8524510C40AEQ33475738-74A2D199-445E-4850-B6C1-CFA61D693182Q33539722-3DC6D3DF-DC25-4C73-8AFC-F1C135635E01Q33885289-D631A2BB-6FC9-4633-BD3D-076ED0D3FB70Q33936902-C7272AF6-4C7D-4EF2-981B-FD48FCB3DA86Q33977500-F0F314A4-D071-4FAF-8AB6-87480DD489BCQ34050464-FFED06BF-39D9-4EEB-A876-A5F16E511844Q34124260-9AF742C2-BCC6-4A8A-993A-E892ECEED602Q34299359-4A3DBFBF-52FE-4CEB-83C3-A8AB9A04B0CCQ34332006-C6DB9D15-EB9D-483E-BE65-301EDA609AE1Q34347798-989D5BC3-8DB8-401F-A6BE-E5AC29F614CFQ34447265-B17A2563-BDA2-4B41-8F23-A1DB9E02DFCEQ34518702-C57BFD32-3AEE-4E17-88CA-737F99F8B4AFQ34549266-03443619-74C2-4A32-9E13-759DF3B903B8Q34608660-4EA87ED1-58F7-4553-A1A5-BD065732F4ADQ34624507-8A16D792-3AD0-4912-9C64-D39508DAFC5BQ34923134-A0CCA479-537B-42FE-8019-33811B03EBECQ35050571-E1D3470D-7698-45BE-B83C-E7A469CA6842Q35311079-18422E43-8C46-4BF2-BE0E-5DDB914FE19AQ35448326-FF3CE796-C5BB-4C56-B3D7-9EB0D792B7AEQ35586308-2222A664-0184-41ED-A5AC-B3962AF6793CQ35666604-66DCDA2B-5E5B-41B8-B48E-72CC9BB887D2Q35755711-E167CA0C-EB3F-4CAC-BB28-A4803615BE31Q36012311-7883E03F-8B1C-4CB6-9E85-70FF7F38BB20Q36517026-05D891BC-F11F-400B-867D-BB96F762309DQ36579479-32924BD1-04F7-46B1-A3AA-A52EA0BEA830Q36709077-208214F7-21D2-43E5-831D-DB3B4BC0B54BQ36863389-14553682-5BFC-4BCE-A444-61723DA06E1EQ36885561-99CEF597-5E73-41C3-A5FA-D70117D1FCFF
P2860
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.
@en
type
label
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.
@en
prefLabel
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.
@en
P2093
P2860
P356
P1433
P1476
Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.
@en
P2093
James I Elliott
Jean-Noel Octave
Mahiuddin Ahmed
Saburo Aimoto
Steven O Smith
Takeshi Sato
P2860
P304
P356
10.1021/BI052485F
P407
P577
2006-05-01T00:00:00Z